Agentix Corp.
AGTX
Other OTC0.02
USD
- -
- -
Agentix Corp.
AGTX
(Other OTC)
Recent
price
0.02
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Agentix Corp. operates as a clinical development-stage biotechnology company specializing in the development and commercialization of novel therapeutics targeting metabolic diseases in the United States. Its primary products include AGTX-2004, a peripherally-acting CB1 receptor antagonist demonstrating efficacy in animal models for obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist aimed at treating obesity and non-alcoholic fatty liver diseases. The company focuses on producing pharmaceutical-grade biocomplexes with applications in dermatology, oncology, and neurology, utilizing proprietary cellular delivery technology. Agentix Corp. was founded in 2020 and is headquartered in Dana Point, California. Recent strategic developments include the company's continued advancement of its drug candidates in clinical stages, maintaining a focus on metabolic disorders. There are no public records of acquisitions or major funding rounds in the past year, but the company emphasizes innovation in pharmaceutical products for specific clinical applications. The company underwent a significant rebranding, having formerly been known as FairWind Energy, Inc. before changing its name to Agentix Corp. in June 2019. It operates primarily in the U.S. market, targeting metabolic disease therapies with potential for global expansion as clinical trials and product development progress. Agentix's business segments include biotechnology and pharmaceuticals, with research and development concentrated on products addressing obesity, diabetes, and liver diseases. It primarily serves healthcare providers, research institutions, and pharmaceutical partners. The company combines consumer wellness and pharmaceutical product opportunities by integrating cellular delivery technology in its medical, bioceutical, hemp, and CBD industry ventures, aiming to deliver sophisticated therapeutic solutions for metabolic and related conditions. Overall, Agentix Corp. positions itself as a clinical-stage biopharmaceutical company focused on therapeutic innovation in metabolic diseases, leveraging proprietary delivery platforms and targeted drug candidates to establish its presence in the evolving pharmaceutical landscape. Recent public information highlights a commitment to product development and commercialization in the metabolic disease space without notable mergers or acquisitions in the last one to two years. The company operates from its headquarters in Dana Point, California, serving the U.S. market with potential expansions pending clinical success.